Evidence record · ER-BREMELANOTIDE-HSDD-030
Does bremelanotide improve HSDD symptoms?
US-authorised bremelanotide improves desire and related distress in premenopausal women with acquired, generalised HSDD
US-authorised bremelanotide improved sexual desire and related distress in phase 3 trials of premenopausal women with acquired, generalised HSDD. This supports the narrow labelled claim. It does not establish UK authorisation, benefit for other populations or conditions, or equivalence to PT-141 products sold online.
Claim boundary
What this verdict covers
The verdict follows the US label’s diagnosis, sex and menopausal-status boundaries and the phase 3 outcomes. It does not cover erectile dysfunction, relationship difficulties or general libido enhancement.
- Compound
- Bremelanotide
- Population
- Premenopausal women with acquired, generalised hypoactive sexual desire disorder
- Outcome
- Sexual desire and related distress
- Record ID
- ER-BREMELANOTIDE-HSDD-030
Evidence synthesis
What the research can support
Two large randomised phase 3 trials reported statistically significant improvement in desire and related distress versus placebo, with nausea and other adverse effects common enough to matter. FDA authorisation defines the exact population and contraindications.
Why the confidence is high
Average improvements were modest, individual response varies and the label includes blood-pressure and pigmentation precautions. There is no identified UK authorisation.
Decision boundary
What this record cannot tell you
This record cannot identify the contents, strength, purity, sterility or stability of a particular vial. It does not provide a dosing plan, administration instructions or a personal treatment recommendation. A supported narrow outcome cannot be transferred to a different route, population or product.
This publication has not independently tested a product for this record. Product evidence belongs to a named batch and method; clinical evidence belongs to the intervention actually studied.
From our work: how we checked this claim
ER-BREMELANOTIDE-HSDD-030 addresses one bounded question: Does bremelanotide improve HSDD symptoms?. Yianni Kiromitis checked the search record, source descriptions, study design, population, intervention identity, comparator and patient-important outcomes against the published evidence method. The source ledger contains 3 primary or official sources. Each was assigned only the proposition it can support; a regulatory document was not treated as a treatment trial, and an animal or laboratory finding was not presented as a dependable human outcome.
The recorded evidence basis is Relevant human, the verdict is Supported and confidence is High. Eleni Kiromitis reviewed study design, biomedical evidence, laboratory context and analytical limits. Dr Stavroula Nikitopoulou reviewed the clinical claim, adverse effects, contraindications, red flags and patient-facing safety wording. Both completed their assigned review on 10 August 2026. Yianni retained publication and correction responsibility. The review notes identify which source supports each material claim and which limitation must remain beside the conclusion.
No direct product testing, seller data, personal treatment experience or patient experience was used to set this verdict. The record cannot establish the contents, strength, purity, sterility or stability of a particular vial, and it does not provide dosing, administration or personalised treatment advice. A finding cannot be transferred to a different route, population, product or outcome without new evidence. We also checked the visible review date against the publication record and structured data. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Source ledger
Evidence used for this verdict
Each source supports only the proposition stated beside it. Regulatory scope and study scope remain visible.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| RECONNECT phase 3 bremelanotide trials | The trials found improvements in desire and related distress versus placebo. | They do not support other populations or unverified PT-141 products. | 10 August 2026 |
| US Vyleesi prescribing information | The label defines the authorised population, contraindications, warnings and outcomes. | A US label is not a UK authorisation. | 10 August 2026 |
| FDA bremelanotide approval letter | The letter records the US marketing-approval decision. | It does not verify online products or create broader indications. | 10 August 2026 |
Quick answers
Frequently asked questions
What is the verdict on Bremelanotide for this claim?
The verdict is supported for the precise claim stated on this page. It combines the evidence type, directness, consistency and study limits; it is not a rating of the compound as a whole. The confidence field shows how readily new evidence could change the conclusion.
What evidence supports this verdict?
Two large randomised phase 3 trials reported statistically significant improvement in desire and related distress versus placebo, with nausea and other adverse effects common enough to matter. FDA authorisation defines the exact population and contraindications. The source ledger below links the primary or regulatory records used and states what each source cannot establish.
Does this evidence apply to a peptide vial sold online?
No. A study or authorisation applies to the exact material, formulation, route, population and controls that were evaluated. It cannot verify the identity, amount, purity, sterility, stability or delivery of a separate vial. Those are batch-specific product questions, not automatic extensions of an efficacy result.
Is Bremelanotide authorised in the UK for this use?
Bremelanotide is US-authorised for a narrow HSDD indication. No UK marketing authorisation was identified; US approval does not transfer to UK products or practice. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What should competitive athletes know?
Bremelanotide is not specifically named on the 2026 WADA Prohibited List. Athletes should still check current rules and medicine documentation. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion. Read the cited source and stated scope together before relying on it.
What could change this verdict?
Material US label changes, a UK regulatory decision, longer-term safety evidence or new high-quality comparative trials in the labelled population. Any update would be dated and recorded through the site correction and version process. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
Continue the investigation